Clinic
Sasaki Medical LLC
Sasaki Medical LLC was paid $24.05M by Medicaid between Apr 2018 and Dec 2024, across 22 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoSASAKI MEDICAL LLC
ROSEVILLE, MN 55113
ROSEVILLE, MN 55113
33aNPI1326490475assigned 07/12/2016
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$24.05M
24GClaims233,567
24DCodes billed22
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Minnesota
Rank by total paid#3 of 87
Median peer was paid$1.04M
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 968 | $37K | |
| 2019 | 18,698 | $1.97M | |
| 2020 | 31,302 | $4.04M | |
| 2021 | 41,607 | $5.05M | |
| 2022 | 42,727 | $4.37M | |
| 2023 | 56,774 | $4.97M | |
| 2024incomplete | 41,491 | $3.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 74,349 | 44,084 | $7.33M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14% | 62,632 | 38,856 | $3.47M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 11% | 27,478 | 20,512 | $2.69M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 11% | 18,692 | 14,823 | $2.57M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 10,103 | 6,988 | $2.54M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.2% | 8,539 | 6,545 | $1.72M |
| 99205 | Prolong outpt/office vis | 5.5% | 7,664 | 6,898 | $1.31M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.3% | 9,771 | 4,636 | $1.26M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 2,737 | 2,607 | $314K |
| 96131 | <1% | 1,292 | 1,247 | $178K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 2,287 | 2,023 | $142K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | <1% | 1,336 | 690 | $138K |
10 more codes
| 96130 | <1% | 1,302 | $125K | |
| 96137 | <1% | 860 | $92K | |
| H0001 | Alcohol and/or drug assessment | <1% | 155 | $36K |
| 80305 | <1% | 2,656 | $32K | |
| 96139 | <1% | 286 | $32K | |
| 96136 | <1% | 859 | $31K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 190 | $11K |
| 96138 | <1% | 286 | $8K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 60 | $5K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 33 | $4K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSASAKI, ALANA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Sasaki Medical LLC | St Paul, MN | $342K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.